More importantly, a randomized trial in which 216 patients hospitalized for COVID-19 were assigned either to discontinuation of ACE inhibitor treatment or to continuation of previously established ACE inhibitor treatment found no difference in the maximum severity of COVID-19 evaluated using the sequential organ failure assessment (SOFA) score [24]. The gene discussed is ACE; the disease is COVID-19.